VRAX — VIRAX BIOLABS GROUP LTD
As of Q2 2026, 1 SEC-registered investment managers reported holding VRAX (VIRAX BIOLABS GROUP LTD) in their latest 13F filings, with a combined reported value of $12 across 4 shares. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 opened new positions. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
VRAX is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| Renaissance Technologies history | Q3 2024 | 145.40K | $282.08K | 0.00% | Add |
| Legal & General Investment Management America history | Q1 2023 | 99.76K | $68.39K | 0.00% | Reduce |
| Bank of America Corp history | Q3 2022 | 8.93K | $28.00K | 0.00% | New |
| Citadel Advisors history | Q2 2025 | 30.16K | $24.67K | 0.00% | Add |
| Millennium Management history | Q2 2023 | 12.58K | $4.90K | 0.00% | New |
| Morgan Stanley history | Q4 2024 | 100 | $225 | 0.00% | New |
| Wells Fargo & Co history | Q2 2024 | 100 | $116 | 0.00% | Hold |
| UBS Group AG history | Q2 2026 | 4 | $12 | 0.00% | New |
New Positions (Q2 2026)
- UBS Group AG 4 sh · $12
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 8 funds)
| Fund | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UBS Group AG | 12.20K | 6.18K | 3.07K | — | 147 | 665 | 2.58K | 5.60K | 20.53K | 37.91K | 22.43K | — | 3.36K | 7.49K | 4 |
| Citadel Advisors | — | — | — | — | 16.36K | — | 14.79K | — | — | — | 13.54K | 30.16K | — | — | — |
| Morgan Stanley | — | 853 | — | — | — | — | — | — | — | 100 | — | — | — | — | — |
| Renaissance Technologies | — | 11.40K | — | 24.60K | — | — | — | 11.00K | 145.40K | — | — | — | — | — | — |
| Bank of America Corp | 8.93K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Legal & General Investment Management America | — | 102.61K | 99.76K | — | — | — | — | — | — | — | — | — | — | — | — |
| Millennium Management | — | 15.39K | — | 12.58K | — | — | — | — | — | — | — | — | — | — | — |
| Wells Fargo & Co | — | — | — | 2.00K | 2.00K | 200 | 100 | 100 | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details